Improving treatment for glioblastoma with a specific genetic change
Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma
This project explores how to make a new drug work even better for people with a specific type of brain tumor called MDM2-amplified glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11135358 on NIH RePORTER |
What this research studies
Glioblastoma is a very aggressive brain cancer, and some of these tumors have a specific genetic change called MDM2 amplification. This change makes a critical tumor-fighting protein, p53, inactive, allowing cancer cells to grow. Researchers are developing new drugs, called MDM2 inhibitors, to target this pathway and restore p53's function. This project aims to understand why one of these drugs, brigimadlin, is particularly effective against MDM2-amplified glioblastoma. We hope to find new ways to combine it with other treatments to maximize its impact and create more powerful strategies against these challenging tumors.
Who could benefit from this research
Good fit: Patients with glioblastoma that has a specific genetic change called MDM2 amplification would be the focus of this research.
Not a fit: Patients whose glioblastoma does not have MDM2 amplification may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective treatment strategies for patients with MDM2-amplified glioblastoma, potentially improving their outcomes.
How similar studies have performed: MDM2 inhibitors are already in advanced clinical development for various cancers, suggesting promising results in other contexts, but this specific combination strategy for glioblastoma is being explored.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.